newsfilter
← Latest News
Business Wire·

DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Enrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth Restriction Trial; Key Opinion Leader Call and Topline Results to Be Held in September Positive Topline Results from Phase 2 Late-Onset